NMDAR antagonists D-(−)-2-amino-5-phosphonopentanoic acid (D-AP5; Cat# 0106) and 3,5-dimethyl-tricyclo-(3.3.1.13,7) decan-1-amine hydrochloride (memantine, Cat# 0773), group 1 mGluR agonist (RS)-3,5-dihydroxyphenylglycine (DHPG; Cat# 0342), and kainate (KA; Cat# 0222) were purchased from Tocris Bioscience (Bristol, UK).
In vitro, drugs were applied to the slice perfusion bath, as previously described.4 (link) In vivo, drug or vehicle control was administered by intraperitoneal (IP) injection or, for experiments requiring cortical drug microinjection (1 hour prior to ctDCS) by a 30G injection tube coupled to a 10μl Hamilton syringe and a perfusion pump (NE-1000, New Era Pump Systems, Farmingdale, NY).
In vitro, drugs were applied to the slice perfusion bath, as previously described.4 (link) In vivo, drug or vehicle control was administered by intraperitoneal (IP) injection or, for experiments requiring cortical drug microinjection (1 hour prior to ctDCS) by a 30G injection tube coupled to a 10μl Hamilton syringe and a perfusion pump (NE-1000, New Era Pump Systems, Farmingdale, NY).
